人工智能生成模型预测酒精相关性肝炎90天生存率:一项全球队列研究
该研究基于全球23个中心12个国家的回顾性队列,利用三种人工智能算法构建集成模型,整合年龄、性别、肝硬化及9项实验室指标与中心特异性死亡率,开发出ALCHAIN评分。验证队列30天和90天AUC分别为0.811和0.799,显著优于传统模型(P<0.001),且ALCHAIN评分>0.20者使用类固醇可改善30天生存。
要点
- ALCHAIN评分在验证队列中30天和90天AUC分别为0.811和0.799,显著优于传统模型(P<0.001)。
- ALCHAIN评分>0.20的患者使用类固醇可改善30天生存,推导与验证队列均一致。
- 该评分整合年龄、性别、肝硬化及9项实验室指标与中心特异性死亡率,可在网页计算。
核心结论
- 基于全球联盟的人工智能评分系统在预测酒精相关性肝炎30天和90天死亡率方面优于传统模型,有益于临床试验、类固醇治疗及移植适应症。
研究设计与样本
- 全球AlcHep倡议回顾性研究,纳入12个国家23个中心符合美国国家酒精滥用与酒精中毒研究所(NIAAA)标准的酒精相关性肝炎患者。
- 中心分为推导队列(11个中心,860例)和验证队列(12个中心,859例)。
- 使用随机森林、梯度提升机、极端梯度提升三种算法构建集成模型,经贝叶斯更新整合推导队列平均90天死亡率与各中心近似死亡率生成后验概率。
主要发现
- 推导队列30天死亡率为18.7%,90天死亡率为27.9%;验证队列分别为21.7%和32.5%。
- ALCHAIN评分在校准方面也优于MELD及其变体。
- 在推导和验证队列中,ALCHAIN评分>0.20的患者使用类固醇可改善30天生存。
关键数值与推荐
- ALCHAIN评分整合年龄、性别、肝硬化及9项实验室指标,并纳入中心特异性死亡率。
- 推导队列30天死亡率18.7%、90天死亡率27.9%;验证队列30天死亡率21.7%、90天死亡率32.5%。
- ALCHAIN评分>0.20的患者使用类固醇可改善30天生存。
- 评分在线获取地址:https://aihepatology.shinyapps.io/ALCHAIN/。
临床怎么用
- 原文指出该评分有益于临床试验、类固醇治疗及移植适应症。
- 原文报告ALCHAIN评分>0.20的患者使用类固醇可改善30天生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence in a global cohort, we sought to derive and validate an enhanced prognostic model. APPROACH AND RESULTS: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled patients with AH per National Institute for Alcohol Abuse and Alcoholism criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients). Focusing on 30 and 90-day postadmission mortality, 3 artificial intelligence algorithms (Random Forest, Gradient Boosting Machines, and eXtreme Gradient Boosting) informed an ensemble model, subsequently refined through Bayesian updating, integrating the derivation cohort's average 90-day mortality with each center's approximate mortality rate to produce posttest probabilities. The ALCoholic Hepatitis Artificial INtelligence Ensemble score integrated age, gender, cirrhosis, and 9 laboratory values, with center-specific mortality rates. Mortality was 18.7% (30 d) and 27.9% (90 d) in the derivation cohort versus 21.7% and 32.5% in the validation cohort. Validation cohort 30 and 90-day AUCs were 0.811 (0.779-0.844) and 0.799 (0.769-0.830), significantly surpassing legacy models like Maddrey's Discriminant Function, Model for End-Stage Liver Disease variations, age-serum bilirubin-international normalized ratio-serum Creatinine score, Glasgow, and modified Glasgow Scores ( p < 0.001). ALCoholic Hepatitis Artificial INtelligence Ensemble score also showcased superior calibration against MELD and its variants. Steroid use improved 30-day survival for those with an ALCoholic Hepatitis Artificial INtelligence Ensemble score > 0.20 in both derivation and validation cohorts. CONCLUSIONS: Harnessing artificial intelligence within a global consortium, we pioneered a scoring system excelling over traditional models for 30 and 90-day AH mortality predictions. Beneficial for clinical trials, steroid therapy, and transplant indications, it's accessible at: https://aihepatology.shinyapps.io/ALCHAIN/ .
引用
- Dunn W, Li Y, Singal AK, et al. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. Hepatology. 2024. PMID: 38607809. doi:10.1097/HEP.0000000000000883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。